Conditions: Schizophrenia
Keywords: PF-02545920 schizophrenia outpatient safety efficacy suboptimal response
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 240
Healthy volunteers: no

Brief summary:
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 from baseline compared to placebo.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: PF-02545920 intervention 2: Placebo intervention 3: PF-02545920
Intervention descriptions: intervention 1: PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit intervention 2: Placebo BID until the Week 12 visit intervention 3: PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit

Protocol document: